Treats acne vulgaris. ANDA 218560, held by Zydus Lifesciences. Tretinoin.
As of Nov 15, 2026, ANDA 218560 (Tretinoin), held by Zydus Lifesciences, was first approved by FDA on Sep 15, 2026, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 15, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tretinoin0.025% · cream;topical | Tretinoin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
